{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:02:25Z","timestamp":1781244145606,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T00:00:00Z","timestamp":1360800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s12094-013-1015-3","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T07:13:47Z","timestamp":1360739627000},"page":"965-968","source":"Crossref","is-referenced-by-count":5,"title":["Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens"],"prefix":"10.1007","volume":"15","author":[{"given":"E. E.","family":"Habib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. S.","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,14]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0049-3848(89)90445-3","volume":"55","author":"MZ Wojtukiewicz","year":"1989","unstructured":"Wojtukiewicz MZ, Zacharski LR, Memoli VA et al (1989) Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. Thromb Res 55:279\u2013284","journal-title":"Thromb Res"},{"key":"1015_CR2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jtcvs.2004.02.021","volume":"128","author":"DJ Sugarbaker","year":"2004","unstructured":"Sugarbaker DJ, Jaklitsch MT, Bueno R et al (2004) Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128:138\u2013146","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1015_CR3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1547-4127(04)00108-2","volume":"14","author":"EH Baldini","year":"2004","unstructured":"Baldini EH (2004) External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 14:543\u2013548","journal-title":"Thorac Surg Clin"},{"key":"1015_CR4","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353:1591\u20131603","journal-title":"N Engl J Med"},{"key":"1015_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0169-5002(02)00180-0","volume":"38","author":"T Berghmans","year":"2002","unstructured":"Berghmans T, Paesmans M, Lalami Y et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:111\u2013121","journal-title":"Lung Cancer"},{"key":"1015_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.1990.8.1.151","volume":"8","author":"D Raghavan","year":"1990","unstructured":"Raghavan D, Gianoutsos P, Bishop J et al (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151\u2013154","journal-title":"J Clin Oncol"},{"key":"1015_CR7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00685720","volume":"27","author":"NJ Vogelzang","year":"1990","unstructured":"Vogelzang NJ, Goutsou M, Corson JM et al (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukaemia Group B. Cancer Chemother Pharmacol 27:239\u2013242","journal-title":"Cancer Chemother Pharmacol"},{"key":"1015_CR8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","volume":"11","author":"M Hazarika","year":"2005","unstructured":"Hazarika M, White RM, Booth BP et al (2005) Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982\u2013992","journal-title":"Clin Cancer Res"},{"key":"1015_CR9","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"1015_CR10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.1996.14.3.1007","volume":"14","author":"ST Ong","year":"1996","unstructured":"Ong ST, Vogelzang NJ (1996) Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 14:1007\u20131017","journal-title":"J Clin Oncol"},{"key":"1015_CR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00175403","volume":"6","author":"BL Zidar","year":"1988","unstructured":"Zidar BL, Green S, Pierce HI et al (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a southwest oncology group study. Invest New Drugs 6:223\u2013226","journal-title":"Invest New Drugs"},{"key":"1015_CR12","first-page":"1710","volume":"16","author":"FE Millard","year":"1997","unstructured":"Millard FE, Herndon J, Vogelzang MR et al (1997) Gemcitabine for malignant mesothelioma: a phase II study of the cancer and leukemia group B (CALGB 9530). ProcAm Soc Clin Oncol 16:1710","journal-title":"ProcAm Soc Clin Oncol"},{"key":"1015_CR13","first-page":"1784","volume":"17","author":"HG Bischoff","year":"1998","unstructured":"Bischoff HG, Manegold C, Knopp M et al (1998) Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17:1784","journal-title":"Proc Am Soc Clin Oncol"},{"key":"1015_CR14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","volume":"108","author":"VW Rusch","year":"1995","unstructured":"Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 108:1122\u20131128","journal-title":"Chest"},{"key":"1015_CR15","unstructured":"National Cancer Institute: Common Toxicity Criteria Manual, NCI-CTC version 2.0, April 30, 1999. http:\/\/ctep.cancer.gov\/reporting\/ctc.html"},{"key":"1015_CR16","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2003.02.043","volume":"21","author":"VW Rusch","year":"2003","unstructured":"Rusch VW (2003) Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol 21:2629\u20132630","journal-title":"J Clin Oncol"},{"key":"1015_CR17","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2002.10.073","volume":"20","author":"A Hughes","year":"2002","unstructured":"Hughes A, Calvert P, Azzabi A et al (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533\u20133544","journal-title":"J Clin Oncol"},{"key":"1015_CR18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","volume":"24","author":"GL Ceresoli","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24:1443\u20131448","journal-title":"J Clin Oncol"},{"key":"1015_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257\u2013260","journal-title":"Ann Oncol"},{"key":"1015_CR20","first-page":"S220","volume":"49","author":"D Fennell","year":"2005","unstructured":"Fennell D, Steele J, Sheaff M et al (2005) Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 49:S220","journal-title":"Lung Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-013-1015-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-013-1015-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-013-1015-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T12:03:49Z","timestamp":1688040229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-013-1015-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,14]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s12094-013-1015-3","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,14]]}}}